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A recent real-world study comparing lithium and 
valproate alone and in combination reaffirmed 
lithium as an effective first-line drug for maintenance 
therapy and perhaps the best drug for prophylaxis.5 
Recent guidelines state that in addition to its clear 
prophylactic properties, lithium is also efficacious in 
the acute phases of bipolar disorder (Table 1).6
Mania 
Robust randomised controlled data from trials 
indicate that lithium is effective in treating acute 
mania. However, its relatively slow onset of action 
(6–10 days) means it is used in combination with 
short-term antipsychotics and benzodiazepines.1 
Depression
The evidence for lithium monotherapy in the 
treatment of bipolar depression is not as impressive 
as that for mania, partly because it can take 6–8 
weeks to take effect. Recent clinical trials suggest that 
lithium is more effective than placebo and therefore 
it remains an important option for treating bipolar 
depression.7
Maintenance and prophylaxis
The efficacy of lithium in prophylaxis has been 
robustly demonstrated by the BALANCE study.5 With 
adequate adherence, long-term lithium successfully 
reduces suicidal ideation.1 Consistency of treatment is 
therefore important and commencing maintenance 
therapy early provides the best possibility of 
improved long-term outcomes.3 Furthermore, 
long-term therapy may confer neuroprotection by 
enhancing the viability of cells as well as preventing 
apoptosis. 
Rapid cycling bipolar disorder and mixed 
states
Clinically, rapid cycling bipolar disorder and mixed 
states can often be difficult to differentiate1 and in 
practice lithium is relatively less effective in achieving 
remission in both of these subtypes compared to 
bipolar I disorder. However, it does reduce symptom 
severity and can therefore be used combined with 
other psychotropic medications, especially when 
wanting to reduce the risk of suicide and achieve 
prophylaxis.
starting lithium therapy
Lithium is available in a variety of formulations. The 
sustained slow-release formulation will have a lower 
sUMMArY
Lithium has proven efficacy in the treatment 
of bipolar disorder, both for acute mania 
and long-term mood stabilisation and 
prophylaxis. 
It is also useful in combating treatment-
resistant depression. 
Compared to other mood stabilisers, lithium 
has a favourable efficacy–tolerability balance.
Lithium is underused due to active marketing 
of alternatives and concerns regarding 
adverse effects, tolerability, and the 
perception that regular monitoring is difficult. 
Safe and effective use of lithium
introduction
Lithium has been available for over sixty years for 
bipolar disorder. A large empirical evidence base has 
ensured it remains a viable treatment option, even in 
the absence of sponsorship and promotion.1-3
Lithium has unique properties both as an antisuicidal 
and neuroprotective drug and, if used wisely, 
is relatively well tolerated and not complex to 
administer. Despite this, its role as a mood stabiliser 
in practice has been limited because of concerns 
regarding tolerability and long-term risks, and the 
perception that regular and reliable monitoring of 
plasma concentrations is difficult. 
efficacy in bipolar disorder 
Lithium is particularly effective in patients with 
recurrent bipolar I disorder in which episodes of 
depression and mania are punctuated by periods 
of remission (euthymia). Complex forms of bipolar 
disorder such as bipolar II disorder, mixed states, and 
rapid cycling are common, but respond less well to 
lithium (Table 1). 
In recent years the reported response to lithium in 
bipolar disorder has diminished. This is partly because 
studies investigating new treatments, in which lithium 
has often served as a comparator, have increasingly 
used heterogeneous bipolar populations.4 The 
patients usually have mixtures of bipolar disorder 
‘subtypes’ from bipolar I disorder to major depression. 
Studies in first world countries often enrol individuals 
who have been refractory to pharmacotherapy, so not 
surprisingly the efficacy of lithium appears lower than 
expected. 
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peak plasma concentration which may be better 
tolerated by some patients. After oral administration 
lithium is absorbed in the gut and excreted wholly 
via the kidneys. It has very few interactions relating 
to hepatic metabolism. Steady-state lithium 
concentrations can usually be achieved after 4–5 days 
of daily administration. Lithium has a relatively narrow 
therapeutic index so it is important to maintain lithium 
plasma concentrations within a specific range for each 
individual to achieve a balance between efficacy and 
adverse effects. 
To minimise adverse effects when starting lithium de  
novo it should be administered in small divided doses  
then titrated gradually to achieve plasma concentrations 
of 0.6–0.8 mmol/L, while monitoring for these  
effects. Concentrations of up to 0.8–1.0 mmol/L may 
be needed for lithium-naïve patients and for treating 
acute recurrence of mania. Recent long-term studies 
suggest that even relatively low concentrations  
(0.6–0.8 mmol/L) confer reasonable prophylaxis, and 
are better tolerated. 
Maintenance and prophylaxis therapy
The primary aim of prophylaxis is to prevent the 
recurrence of symptoms while minimising adverse 
effects and maintaining compliance. Lithium can be 
given as a once-daily dose for maintenance therapy. 
Most importantly, plasma lithium concentrations 
should be optimised to the symptom profile of 
the individual. Patients more prone to developing 
depressive episodes may benefit from concentrations 
of 0.4–0.8 mmol/L, whereas those more likely to 
become manic may require concentrations of  
0.6–1.0 mmol/L long term. 
short-term adverse effects 
Tremor, general fatigue, diarrhoea, thirst, polyuria, 
nausea, headache and vomiting are common 
initially, but are usually transient (1–2 days) and 
dose dependent. Most of these adverse effects are 
associated with rapid changes in plasma lithium 
concentrations and therefore should be anticipated 
whenever the dose of lithium is altered, and especially 
when it is increased.8 If adverse effects persist for 
weeks or are particularly troublesome, lithium should 
be decreased or stopped. In practice this is rarely 
necessary and lithium can usually be reintroduced 
while titrating the dose carefully.
Long-term adverse effects 
There are several adverse effects associated 
with long-term use of lithium and regular patient 
monitoring is required (Table 2). 
Kidneys
Lithium affects the concentrating ability of the kidney, 
leading to polyuria and secondary thirst, but it is 
controversial whether lithium causes irreversible 
kidney damage. Approximately 10% of patients on 
lithium are prone to developing diabetes insipidus.9 
It is this renal insufficiency which is often thought to 
contribute to end-stage renal failure. Patients with 
renal impairment may remain on lithium treatments 
with appropriate dosage adjustments.
Table 1    Lithium in mood disorders
Bipolar disorder
Acute mania Lithium monotherapy is a first-line option 
Antimanic action can take 6–10 days
In practice lithium is often used in combination with neuroleptics and/or benzodiazepines to 
achieve a more rapid effect
Acute depression Lithium monotherapy is less effective in treating acute depression than it is in treating mania 
Effect of antidepressant action can take 6–8 weeks
Often used to augment mood stabiliser or antidepressant therapy
Maintenance/prophylaxis Lithium is superior to placebo and most anticonvulsants and neuroleptics used in the 
treatment of bipolar disorder 
Outcome is better if therapy is initiated early
Rapid cycling/mixed 
states
Lithium is shown to decrease symptom severity and reduce morbidity, but is less likely to 
achieve remission of symptoms and recovery
Major depression
Acute Lithium monotherapy is superior to placebo but it is rarely used, particularly in acute settings
Greater efficacy for patients with a family history of bipolar disorder
Chronic Often used as an augmentation strategy
Effective in combination with all antidepressants and can be prescribed adjunctively with all 
treatment modalities
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Thyroid
Lithium also affects thyroid function reducing 
the availability of thyroxine. The incidence of 
hypothyroidism is six-fold higher in patients on 
lithium as compared to the general population. 
Hypothyroidism in turn increases the likelihood 
of developing clinical depression.8 Patients on 
lithium should therefore be routinely assessed 
for hypothyroidism and treated with thyroxine 
replacement if indicated.8 It needs to be stressed 
however that hypothyroidism is not a contraindication 
for therapy.
Parathyroid
Parathyroid function can also be compromised by 
lithium. Patients on lithium are therefore prone to 
develop hypercalcaemia secondary to elevated 
parathyroid concentrations. Hyperparathyroidism  
that produces significant hypercalcaemia is a  
possible contraindication for continuing lithium 
so there is a need to monitor plasma calcium 
concentrations.10 
Weight gain
Modest weight gain of 1–2 kg is common (5%) in 
patients on long-term lithium therapy. The trajectory 
of weight gain is steep at the beginning but soon 
plateaus. Diet, exercise and lifestyle advice are 
essential when patients start treatment. 
Teratogenic effects
It appears that the risk of teratogenic effects from 
lithium has been exaggerated in the past.10 However, 
there is a small risk and lithium is best avoided 
during pregnancy. Management during pregnancy 
should be collaborative and requires careful informed 
consideration of the risks. 
toxicity and its management
In acute lithium intoxication, the increase in plasma 
concentrations (>2 mmol/L) can be potentially lethal. 
Once renal excretion reaches its maximum, lithium 
accumulates rapidly and symptoms worsen. However, 
high plasma concentrations may cause relatively 
mild symptoms, and in these instances individuals 
often recover without permanent neurological 
damage. This occurs because lithium can take up to 
24 hours to cross the blood–brain barrier, and brain 
concentrations usually peak eight hours after oral 
administration. 
With lifelong treatment, lithium can gradually 
accumulate within the brain and lead to chronic 
neural toxicity because it has a longer half-life in the 
brain than in plasma. Symptoms such as lethargy, 
drowsiness, muscle weakness and hand tremor are 
indicative of neural toxicity and can manifest even at 
therapeutic concentrations of lithium. Toxicity from 
chronic lithium use is also subject to increases in 
dose and individual factors such as diminished renal 
function and ageing which may result in increased 
plasma concentrations. 
It is therefore essential to monitor patients for 
symptoms of toxicity and assess plasma lithium 
concentrations every 3–6 months. If toxicity occurs, 
treatment should be stopped and prompt action 
taken to prevent serious damage. 
Monitoring lithium
While it is generally recommended that plasma 
lithium concentrations may be monitored every 
3–6 months,11 current evidence suggests that unless 
otherwise indicated, annual monitoring may be 
sufficient (Table 2).
Table 2    recommendations for monitoring patients on lithium
Parameter Investigation When to monitor
Lithium Plasma lithium concentrations * Monitor closely for first few days and aim to achieve 
concentrations within the therapeutic range 
Monitor every 3–6 months for long-term lithium use
Renal function Urea and creatinine
Electrolytes
Baseline then at 6 months
Baseline then annually
Thyroid function Thyroid stimulating hormone 
concentrations
Baseline then at 6 months 
Annually for long-term lithium use
Parathyroid function Calcium concentrations Baseline then annually
Weight Waist circumference, body mass index Baseline then annually
Adapted from guidelines from the International Society for Bipolar Disorders.11 More frequent investigation may be required 
if clinically indicated or a change in mood state is observed.  
*  In the event of acute toxicity (>2 mmol/L), lithium should be ceased immediately and haemodialysis can be used to 
reduce lithium in the blood
Safe and effective use of lithium
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Adherence
Adverse effects are the most commonly cited reason 
for poor adherence. Of these, weight gain is the most 
distressing.8 Not surprisingly, individuals who report 
multiple adverse effects are less likely to be adherent, 
and additional factors such as stigma and acceptance 
of the illness are important to bear in mind.12
The need to take medication when symptom-free is a 
key concern. This viewpoint often reflects a degree of 
denial by the patient because they are feeling better. 
This is more evident in younger individuals, those 
who have been recently diagnosed, and those taking 
lithium long-term. Patients who are not in a strong 
doctor–patient relationship and those who are less 
informed about the disorder and its treatment are 
generally less adherent. 
Enhancing adherence requires a multifaceted 
approach involving education and monitoring of 
the patient. Close monitoring of patients improves 
adherence in two ways. First, it allows tailoring of 
the therapeutic dose to suit the individual, so that 
therapeutic benefit is optimised and the likelihood 
of adverse effects is minimised. Second, regular 
monitoring increases contact and therefore patients 
are likely to receive more frequent supervision and 
better education concerning their illness and its 
management.
Other strategies include educating family and friends 
to recognise the early signs of relapse and using 
a suitable means to manage stressors. Caregiver 
support increases adherence.13 Encouraging patients 
to make a firm commitment to treatment before 
it starts, and coupling pharmacotherapy with 
psychotherapy, have also been shown to improve 
patient outcomes.8
Conclusion
Lithium can be used as monotherapy or in 
combination with other medications for the 
treatment of bipolar disorder. It is most efficacious 
in maintenance and prophylaxis and 
is widely used as a mood stabiliser, 
and has efficacy in both poles of the 
disorder. It is important to monitor 
both response and adverse effects 
and to regularly measure the plasma 
concentrations of lithium. This ensures 
adequacy of treatment and enhances 
compliance. If used wisely, lithium is relatively 
well tolerated and not complex to administer. It 
remains one of a handful of potentially life-changing 
treatments in psychiatry. 
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complex to administer
